Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy : Description of azole-resistance profiles associated with the Y132F ERG11p substitution
© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd..
BACKGROUND: Fluconazole-resistant Candida parapsilosis is a matter of concern.
OBJECTIVES: To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions.
PATIENTS/METHODS: We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility.
RESULTS: Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L.
CONCLUSIONS: We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Mycoses - 67(2024), 3 vom: 04. März, Seite e13706 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mesquida, Aina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 06.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/myc.13706 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369281756 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369281756 | ||
| 003 | DE-627 | ||
| 005 | 20240306233200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/myc.13706 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369281756 | ||
| 035 | |a (NLM)38438313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mesquida, Aina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy |b Description of azole-resistance profiles associated with the Y132F ERG11p substitution |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Fluconazole-resistant Candida parapsilosis is a matter of concern | ||
| 520 | |a OBJECTIVES: To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions | ||
| 520 | |a PATIENTS/METHODS: We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility | ||
| 520 | |a RESULTS: Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L | ||
| 520 | |a CONCLUSIONS: We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C. parapsilosis | |
| 650 | 4 | |a Madrid | |
| 650 | 4 | |a Rome | |
| 650 | 4 | |a Y132F | |
| 650 | 4 | |a fluconazole resistance | |
| 650 | 4 | |a genotyping | |
| 650 | 7 | |a Azoles |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a isavuconazole |2 NLM | |
| 650 | 7 | |a 60UTO373KE |2 NLM | |
| 650 | 7 | |a ibrexafungerp |2 NLM | |
| 650 | 7 | |a A92JFM5XNU |2 NLM | |
| 650 | 7 | |a Voriconazole |2 NLM | |
| 650 | 7 | |a JFU09I87TR |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Anidulafungin |2 NLM | |
| 650 | 7 | |a 9HLM53094I |2 NLM | |
| 650 | 7 | |a Micafungin |2 NLM | |
| 650 | 7 | |a R10H71BSWG |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Triterpenes |2 NLM | |
| 650 | 7 | |a Glycosides |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 700 | 1 | |a Alcoceba, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Padilla, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, Aída |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a González-Romo, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a De Carolis, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Sanguinetti, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Mantecón-Vallejo, María de Los Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Algarra, María |e verfasserin |4 aut | |
| 700 | 1 | |a Durán-Valle, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Ayala, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-García-de-la-Pedrosa, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Del Carmen Martínez-Jiménez, María |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Castellano, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Quiles-Melero, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Cuétara, María Soledad |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-García, Aída |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Escribano, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Guinea, Jesús |e verfasserin |4 aut | |
| 700 | 0 | |a CANDIMAD study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycoses |d 1990 |g 67(2024), 3 vom: 04. März, Seite e13706 |w (DE-627)NLM01265194X |x 1439-0507 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:3 |g day:04 |g month:03 |g pages:e13706 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/myc.13706 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 3 |b 04 |c 03 |h e13706 | ||